STL Index for: Lauren Ching

Neoadjuvant cemiplimab has shown promising results for resectable cutaneous squamous cell carcinoma where surgery may result in significant morbidity. Phase 2 studies demonstrated pathological complete response rates of 51% with event-free survival of 89% at 12 months. The treatment was well-tolerated and may improve surgical outcomes by reducing tumor burden before resection, offering a valuable option for advanced disease.